Gland Pharma Ltd - Poised for Stronger H2 Momentum; Rating Upgraded to BUY
Stable Core and Cenexi Turnaround Drive Revenue Growth: Gland Pharma reported consolidated revenue of Rs 1,487 Cr in Q2FY26, marking a 5.8% YoY...
163 Views
Gland Pharma Ltd - Uptick in Margins; Strong Launch Momentum
Stable Core and Cenexi Turnaround Drive Revenue Growth: Gland Pharma reported consolidated revenue of Rs 1,506 Cr in Q1FY26, marking a 7.4% YoY...
131 Views
Gland Pharma Ltd - Base Business Facing Challenges; New Launches Offer Optimism
Encouraging Financial Performance: GLAND’s base business (Ex-Cenexi) registered a 12.3% YoY revenue degrowth due to price erosion.
168 Views
Gland Pharma - New Launches and Higher Milestone Income Drive Margins
While revenue came in line, product mix and a higher share of milestone income led to better-than-expected margins in the base business.
235 Views
Gland Pharma Ltd - Base Business Faces Volume Decline; New Launches Offer Optimism
GLAND’s base business (Ex-Cenexi) registered an 8% YoY revenue degrowth due to lower volumes; however, EBITDA margins expanded to ~38.7%, improving...
211 Views